SportLinc Receives FDA Clearance: Lincotek Targets Orthopedic OEM Market
Lincotek’s SportLinc Syndesmosis Device has secured FDA 510(k) clearance (K252081), enabling commercial launch for ankle syndesmosis injuries. The single‑use system combines a high‑molecular‑weight polyethylene suture with low‑profile titanium buttons and arrives preloaded in a sterile inserter, streamlining operating‑room workflow. Lincotek is marketing the device as a private‑label platform for orthopedic OEMs, offering a predicate to accelerate their regulatory pathways. The company is also pursuing CE Mark certification to extend the product into European markets.
Defect-Engineered Pt/Nb2O5 Boosts Radical-Driven Benzimidazole Production and Hydrogen Evolution Efficiency
Researchers have created a defect‑engineered Pt/Nb₂O₅ catalyst with abundant oxygen vacancies and platinum nanoparticles that dramatically improves photocatalytic benzimidazole synthesis and concurrent hydrogen evolution. The system delivers 4.0 mmol g⁻¹ h⁻¹ production of 2‑methylbenzimidazole and 10.2 mmol g⁻¹ h⁻¹ hydrogen under mild light, surpassing prior benchmarks....
DeNovix Launches Squid™ Full Range Pipette: A Single Device Covering 1 – 1000 µL
DeNovix unveiled the Squid™ Full Range Pipette, a single instrument that handles volumes from 1 µL to 1000 µL, effectively consolidating three to five conventional pipettes. The device uses Dynamic Volume Control™ with a patented tip selector, allowing users to switch between...
Follow the Money: Autoimmune, Inflammatory Disease Therapies, Antibody-Drug Conjugates, AKT1-Selective Inhibitor Programs
A wave of sizable financing rounds swept the biotech sector in late April 2026, with more than $1.3 billion pledged across 15 companies. Beeline Medicines led the pack with a $300 million Series A to advance lupus‑focused small‑molecule and protein therapeutics, while Sidewinder...
Single-Cell Sequencing Reveals Why some CAR-T Therapies Succeed While Others Fail
Researchers reviewed 44 single‑cell RNA sequencing studies covering about 500 patients to pinpoint cellular traits linked to CAR‑T therapy outcomes. The analysis identified exhaustion marker expression, low memory‑like cell fractions, and limited clonal diversity as hallmarks of relapse, while persistent,...
Global Lassa Virus Research Reveals Critical Knowledge Gaps and Regional Disparities
A new global assessment of Lassa fever research highlights stark knowledge gaps and uneven investment across endemic regions. The report finds that only three of the seven high‑burden countries host active surveillance sites, and funding for Lassa studies trails behind...
Tackling Drug Resistance Must Become Biotech’s Next Frontier
Drug resistance underlies roughly 90% of the 600,000 cancer deaths in the United States each year, limiting the durability of modern therapies. Kairos Pharma, founded in 2013, is focusing on the biology of resistance with its candidate ENV‑105, which aims...
Restoring Vision with Stem Cell–Derived Retinal Cells by Overcoming ILM Barrier
Researchers have shown that disrupting the internal limiting membrane (ILM) enables transplanted human pluripotent stem cell‑derived retinal ganglion cells (hRGCs) to survive, migrate, and mature in the retina of mice, rats and non‑human primates. In eyes with a genetically incomplete...
New Copper Nanozyme Shows Powerful Tumor Suppression with High Precision
Researchers at the Chinese Academy of Sciences have created a coordinatively unsaturated copper single‑atom nanozyme (Cu‑N₂‑CDs) that exhibits markedly higher catalytic activity than traditional Cu‑N₄ nanozymes. The unsaturated Cu‑N₂ sites boost H₂O₂ adsorption by 3.49 times and generate hydroxyl radicals 3.62 times...
Dr. Reddy’s Announces Health Canada Approval of Generic Semaglutide Injection
Dr. Reddy’s Laboratories received a Notice of Compliance from Health Canada, becoming the first firm to secure market authorization for a generic semaglutide injection in Canada. The approval covers both 2 mg and 4 mg pen formulations, and the company is preparing...
New Genome Editing Method Could Swap Entire Genes and Correct 1000 Mutations at Once
Scientists have unveiled a new genome‑editing platform called prime assembly that can insert DNA segments up to 11,000 base pairs, enabling the replacement of entire genes rather than single‑point edits. The method uses overlapping flaps to attach donor DNA without...
Cartesian Therapeutics Inc (RNAC) Q1 2026 Earnings Call Transcript
Wave Life Sciences reported a Q1 net loss of $46.9 million, with cash reserves of $243.1 million expected to fund operations into 2027. The DMD candidate WVE‑N531 delivered a statistically significant 3.8‑second improvement in time‑to‑rise and 7.8% average dystrophin expression,...
All Life Runs on 20 Amino Acids. These Cells Run Key Machinery on Just 19
Scientists have engineered Escherichia coli to run its ribosome—a core protein‑making machine—using only 19 of the standard 20 amino acids, eliminating isoleucine. The breakthrough leveraged AI tools such as AlphaFold and protein language models to redesign protein sequences without compromising...
Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Transcript
Syndax Pharmaceuticals reported $172 million total revenue for 2025, driven by $124.8 million from its menin inhibitor RevuForge and $151.6 million from the chronic‑GVHD therapy Nictimvo. RevuForge posted 38% quarter‑over‑quarter revenue growth and reached roughly 50% penetration of the KMT2A AML population, while...
Alnylam Pharmaceuticals Inc (ALNY) Q1 2026 Earnings Call Transcript
Alnylam reported a strong Q1 2021 performance, with total product sales reaching $135.8 million, an 89% year‑over‑year increase. ONPATTRO generated $102 million in revenue, growing 13% quarter‑over‑quarter, while newly launched OXLUMO contributed $9 million and GIVLAARI $24.7 million. The company announced positive Phase 3 data...
Pro-Dex Inc (PDEX) Q3 2026 Earnings Call Transcript
Becton Dickinson reported Q3 fiscal 2025 revenue of $5.5 billion, up 8.5% year‑over‑year and 3% organically, while adjusted gross margin rose to 54.8% and adjusted EPS reached $3.68, beating expectations. The company announced a definitive agreement to divest its Biosciences and...
Kymera Therapeutics Inc (KYMR) Q1 2026 Earnings Call Transcript
Kymera Therapeutics reported Q1 2026 revenue of $2.8 million, entirely from its Gilead collaboration, and ended the quarter with $978.7 million in cash, extending its runway into the second half of 2028. The company completed enrollment and dosing for the Phase Ib atopic...
Genome Pioneer Craig Venter Dies: Here’s How He Transformed Science
Craig Venter, the maverick who led the private race to sequence the human genome, died at 79. He pioneered whole‑genome shotgun sequencing, enabling rapid, cost‑effective assembly of DNA and co‑founded Celera Genomics to produce a draft human genome alongside the...
PLANeT: Understanding and Leveraging the Genome of Land Plants for a Sustainable Future
Land plants support ecosystems and human civilization, yet reference genomes exist for only a fraction of taxa—95% of genera, 70% of families and 51% of orders remain unsequenced. The PLANeT initiative proposes an international consortium of about 100 laboratories to...
Angiocrine Signaling Drives Liver Fibrosis: From Mechanism to Early Clinical Translation
Researchers led by Hu et al. discovered that ROCK2 activity in liver sinusoidal endothelial cells is a pivotal driver of liver fibrosis. Single‑cell transcriptomics and knockout models revealed that ROCK2‑mediated cytoskeletal remodeling releases angiocrine factors that activate hepatic stellate cells. Early...
Long-Lived Immune Cells Show Promise Against Cancer in World-First Trial
A world‑first clinical trial tested CAR‑T therapy enriched with stem‑cell memory T cells, a long‑lived immune subset. In a small cohort of 11 patients with refractory blood cancers, five achieved complete remission and one partial remission, outperforming historical outcomes of...
Trial of Non-Invasive Endometriosis Scan Boosts Hopes for Quicker Diagnosis
A small trial of 19 women showed that the experimental radiotracer maraciclatide can illuminate endometriotic lesions on a Spect‑CT scan, matching surgical findings in 16 cases with no false positives. Current diagnosis in the UK often requires invasive laparoscopy, leading...
Tiny Biotech’s Experience Raises Questions About FDA’s Rare Disease Policies
BioCentury’s website now publishes a detailed cookie policy that separates cookies into five categories: strictly necessary, functional, marketing, advertising, and analytics. Strictly necessary cookies are always active and essential for authentication and navigation, while functional cookies enable personalization of the...
In Chiesi’s Biggest M&A Deal yet, Pharma Buys HAE Company KalVista
Italian pharmaceutical group Chiesi announced the acquisition of U.S. biotech KalVista for approximately $1.5 billion in cash, marking its largest M&A transaction to date. KalVista, a specialist in hereditary angioedema (HAE), brings a late‑stage monoclonal‑antibody program and a pipeline of complement‑targeted...
Long a Dream, It's Now Real: A Fast and Accurate TB Test that Doesn't Need Phlegm
A Chinese firm, Pluslife, has commercialized the MiniDock MTB, a portable tuberculosis test that works with a simple tongue swab or sputum and costs about $300 per device and $3‑4 per assay. In a study of nearly 1,400 patients across...
BIOTECanada Responds to Health Canada’s Gazette on Modernizing Clinical Trials Regulations
Health Canada has released a Gazette notice proposing modernized clinical‑trial regulations and draft guidance for decentralized trials. BIOTECanada welcomed the initiative but urged that the new rules align with the U.S. FDA and European EMA to avoid duplicative requirements. The...
GLP-1 Drugs May Lower CV Risk in TAVI Patients With Diabetes or Obesity
A retrospective analysis of 1,708 matched TAVI patients shows that glucagon‑like peptide‑1 (GLP‑1) receptor agonists cut the relative risk of major adverse cardiovascular events (MACE) by 37% and all‑cause mortality by 39% at one year. The benefit was consistent in...
MIMEDX Announces First Quarter 2026 Operating & Financial Results
MiMedx Group reported first‑quarter 2026 net sales of $59 million, a 33% drop from the prior year, as new Medicare reimbursement rules crippled its wound‑care segment, which fell 60%. The surgical franchise bucked the trend, posting a 13% year‑over‑year increase. Management...
Medtronic Wins FDA Approval for Updated Mitral Replacement Valve
Medtronic announced FDA approval for its next‑generation Mosaic Neo bioprosthetic mitral valve and has begun U.S. launches. The valve can be implanted via traditional sternotomy or minimally invasive approaches, and the company performed the first combined implant with its Penditure left‑atrial‑appendage...
Smallest-of-Its Kind Probe Tracks Several Key Health Signals
Researchers at the University of Texas at Austin have unveiled a 1.1 mm diameter fiber probe that can simultaneously monitor glucose, lactate, and ethanol in tissue. The mid‑infrared device uses two silver‑halide fibers and a quantum cascade laser to deliver real‑time,...
Rockwell Automation and Cytiva Launch Platform to Accelerate Digital Transformation for Biopharma Companies
Rockwell Automation and Cytiva have launched Figurate, a supervisory control and data acquisition (SCADA) platform aimed at streamlining digital integration in biopharmaceutical manufacturing. The system combines Cytiva’s bioprocessing hardware with Rockwell’s FactoryTalk software, offering an open‑architecture layer that connects third‑party...
AI Drug Target Platform Pairs Prediction with Benchmarking to Improve Early Discovery
Insilico Medicine unveiled an integrated AI framework that couples its Target Identification Pro (TargetPro) predictive engine with the TargetBench 1.0 benchmarking suite to improve early‑stage drug target discovery. The system uses disease‑specific models trained on 22 omics and text scores,...
Early Data Links Wegovy to Risk of 'Eye Stroke' — Here's What to Know
Early signals from a British Journal of Ophthalmology analysis suggest Wegovy, the semaglutide‑based weight‑loss injection, may be linked to ischemic optic neuropathy (ION), a rare form of eye stroke that can cause rapid vision loss. The study examined 31,774 FDA...
Revolving Doors and Efficient Engines: How Proteins Escape a Molecular Tangle
Researchers at the Weizmann Institute revealed that the AAA+ disaggregase ClpB moves protein substrates via a Brownian‑motor, revolving‑door mechanism rather than the previously assumed hand‑over‑hand pulling. Real‑time three‑color fluorescence tracking showed a protein segment threading through the channel in just...
New York Center Ranks Academic Institutions for ‘Industrial Readiness’
The Cure innovation center in New York City unveiled an "industrial readiness" index that evaluates more than 300 U.S. academic institutions on their ability to turn biomedical research into commercial products. Rankings place Harvard, Stanford, Penn, MIT and UCSF at...
AbbVie Faces Questions About Skyrizi Competition From J&J
AbbVie’s first‑quarter earnings call highlighted growing pressure on its immunology franchise as analysts probed the company’s defense against Johnson & Johnson’s upcoming IL‑23 inhibitor. Skyrizi, AbbVie’s flagship psoriasis drug, posted $1.2 billion in Q1 sales, a 12% year‑over‑year increase, but faces...
AbbVie Tops Q1 Estimates, Raises Outlook and Discontinues Cancer Candidate
AbbVie reported $15 billion in first‑quarter revenue, a 12.4% year‑over‑year increase, driven by strong immunology and a 26% surge in neuroscience sales. Immunology products Skyrizi and Rinvoq generated $7.29 billion, while the migraine drug Qulipta boosted neuroscience revenue to $2.87 billion. The company...
“Click Clotting” Technique Rapidly Creates Stronger Blood Clots
Researchers at McGill University unveiled a "click clotting" method that chemically links red blood cell surface proteins, forming a biocompatible cytogel within five seconds. The engineered blood clots are 13 times more fracture‑tough and four times more adhesive than natural...
Molecular Quantum Nanosensors Reveal Temperature and Radical Signals Inside Living Cells
Researchers at Japan's National Institutes for Quantum Science and Technology, the University of Tokyo, and Kyushu University have unveiled molecular quantum nanosensors (MoQNs) that operate inside living cells. The sensors, built from pentacene spin qubits in para‑terphenyl nanocrystals and coated...
Axoft Secures $55M Series A Financing
Axoft, a Cambridge‑based neurotechnology firm, announced a $55 million Series A round led by C.P. Group Innovation, bringing its total funding to over $60 million. The capital will finance global expansion of clinical trials for its implantable brain‑computer interfaces (iBCIs) and support U.S....
Genome Editing Can Be Risky. Meet the Epigenome Editors
Scientists are turning to epigenome editors—tools that rewrite gene activity without altering the DNA sequence—to sidestep the safety concerns of traditional genome editing. By coupling dead Cas9 (dCas9) with epigenetic modifiers, researchers can turn genes on or off with high...
FDA to Pilot Real-Time Clinical Drug Trials Through Cloud and AI
The FDA announced a pilot that will stream clinical‑trial data to the agency in real time using cloud platforms and artificial‑intelligence analytics. Commissioner Marty Makary said the effort could shave up to 40% off the time between Phase 1 trials and...
Supply Chain Digital Twins: An Evolution, Not a Breakthrough
Researchers at NIST and EMD Millipore argue that digital twins can model the intricate biopharmaceutical supply chain, from demand shocks to distribution bottlenecks. By creating in‑silico replicas of cells, raw materials, and logistics flows, twins could identify alternative distribution centers and...
Milk Exosomes Transform Therapeutic Bioprocessing
Milk-derived extracellular vesicles, known as milk exosomes, are emerging as a biocompatible platform for therapeutic delivery. Researchers have loaded the JAK inhibitor tofacitinib into exosomes (mEXOs@TOF) for ulcerative colitis, achieving high drug‑loading efficiency, stability and strong anti‑inflammatory effects without toxicity....
Hopes Raised for More Sustainable Oligonucleotide Manufacturing
QurAlis CTO Hagen Cramer says enzymatic synthesis could make large‑scale oligonucleotide production far more sustainable than the solvent‑intensive solid‑phase method. While solid‑phase synthesis remains fast and automated, it generates high process mass intensity due to extensive solvent washes. Enzymatic, aqueous‑based...
Adaptive, Agent-Oriented Control for Biomanufacturing Systems
The Adaptive Agent‑Oriented System Control (AAOSC) framework, created by the Technical University of Denmark and SiC Systems, adds a decentralized layer of autonomous agent "hives" to biomanufacturing plants. By linking digital twins, IoT sensors and enterprise systems, AAOSC can reduce...
Prenatal Surgery for Spina Bifida May Get a Boost From Stem Cells
Researchers at UC Davis have performed the first in‑utero repair of spina bifida using a stem‑cell‑infused patch on six fetuses. The procedure appeared safe, with no infections, tumors, or delayed healing reported in the initial cohort. While early safety data...
Astellas’s R&D Head Talks Strategy Ahead of Looming Patent Cliff
Astellas Pharma faces a looming patent cliff as its blockbuster prostate‑cancer drug Xtandi, which generated about $4.6 billion in the 2025 fiscal year, loses U.S. patent protection next year. To offset the expected revenue hit, chief R&D officer Tadaaki Taniguchi is accelerating...
Henlius and Organon Gain EC Approval for Pertuzumab Biosimilar
Henlius and Organon have received the first European marketing authorization for a pertuzumab biosimilar, Poherdy, targeting HER2‑positive breast cancer. The EC approval mirrors the product’s earlier U.S. clearance and covers all indications of Roche’s reference drug, Perjeta, including metastatic, neoadjuvant...
Pfizer Earns Positive Phase 3 in Multiple Myeloma; ICON Overstated Revenue
Pfizer announced that its antibody‑drug conjugate Elrexfio achieved a statistically significant and clinically meaningful improvement in progression‑free survival for patients with double‑class exposed relapsed or refractory multiple myeloma. The Phase 3 trial met its primary endpoint, positioning the drug as a...